| Betterchem |
|
|
| FDA approval activities
for this prescription drug:
Flolan (epoprostenol sodium) Injection, Glaxo Wellcome NDA 20-444/S-003 4/14/00 4/17/00 4/17/00 1/7/02 Flolan Indication: Long-term intravenous treatment of pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III & Class IV patients who do not respond to conventional therapy. |
© 2007 Betterchem Corp.
|